INTRODUCTION

C
linical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease-modifying antirheumatic drugs (DMARDs) (1) (2) (3) (4) . At about the same time as the European approval of the third anti-TNFα agent (adalimumab) for treating RA patients, the Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of RA patients treated with biological response modifiers, which contains all of the demographic and clinical parameters, as well as the therapeutic data, usually needed to follow RA patients Reumatismo, 2008; 60(4) : [290] [291] [292] [293] [294] [295] Abbreviations: DMARDs = disease-modifying antirheumatic drug; NSAIDS = non-steroidal anti-inflammatory drug; MTX = methotrexate; anti-CCP = anti-cyclic Citrullinated Peptide Antibodies; RF = rheumatoid factor; SJC = swollen joint count; TJC = tender joint count; ESR= erythrocyte sedimentation rate; CRP = C-creative protein; DAS28 = disease activity score 28; VAS = visual analogue scale; HAQ = health assessment questionnaire.
SOMMARIO
L'artrite reumatoide (AR) è una patologia ad andamento cronico, caratterizzata da sinovite persistente, progressiva distruzione delle strutture articolari e disabilità. Gli agenti biologici anti-Tumor Necrosis Factor-α (TNF-α) (etanercept, infliximab e adalimumab) sono dotati di attività anti-infiammatoria, mediata dalla neutralizzazione del TNF-α, e presentano alcuni importanti vantaggi rispetto ai "Disease-Modifying Anti-rheumatic Drugs" DMARDs. Gli agenti-anti-TNF-α sia in monoter-
which had to be continued for at least nine months. The guidelines also included a recommendation that rheumatologists should register all treated patients in a national register in order to study long term safety. Since 1999, all of the patients with RA diagnosed on the basis of the ACR criteria (6) and treated with at least one dose of an anti-TNF agent have been recorded in a database shared by four Rheumatology Centres in Lombardy (northern Italy): the Lombardy Rheumatology Network (LORHEN) registry.
THE LORHEN REGISTRY
This registry describes the efficacy and safety of the first three years of treatment in a large cohort of patients with RA treated with the three currently available TNF inhibitors: etanercept, infliximab and adalimumab (ETA, INF, ADA).
Baseline
All of the patients with rheumatic disease who start therapy with a biological agent are asked to give their consent to being entered in the registry, after which the consultant completes a standard baseline form including demographic data, the 1987 ACR criteria for RA (6) , the individual components of the DAS28 (7), details of all previous and current DMARD therapy, and comorbidities; the registry does not collect radiological data. The are also asked to provide additional data concerning their smoking habits and occupational history, and to complete the Italian version of the Disability Index of the Health Assessment Questionnaire (HAQ) (8) and the Medical Outcome Survey Short Form 36 (SF-36) assessing the quality of life (9) .
Assessments
At baseline, and after six and 12 months of followup, the treating rheumatologist records each patient's tender and swollen joint counts (28 joints), the patient's assessment of pain on a 100 mm visual analogue scale (VAS), the patient's overall assessment of general health on a 100 mm VAS, disability as measured by the Italian version of the HAQ, the erythrocyte sedimentation rate (ESR) measured using the Westergren method (mm/hour), C-reactive protein (CRP) level, rheumatoid factor (RF), the presence of morning stiffness, the use of DMARDs and/or biological therapy (including details of the start and end of treatment and reasons for treatment termination), concomitant therapies with glucocorticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs), and any adverse events. In addition to being evaluated individually, these measures are also used to compute the DAS28 and to define patient response to treatment on the basis of the EULAR criteria (7, 10, 11). The reasons for discontinuing anti-TNF therapy are classified into three major categories: adverse events, inefficacy (both primary lack of efficacy and secondary loss of efficacy), and other reasons. In the case of a switch from one TNF inhibitor to another, only the first course is considered.
Follow-up
All of the patients are followed up for three years, including those who stop therapy or switch to another biological agent, using three approaches: -Every six months, the attending rheumatologists are asked to provide details of any changes in therapy, current disease activity (DAS28) and, specifically, the occurrence of any adverse event. -The patients are surveyed every six months (for three years), and asked to complete a diary including any new diagnoses, significant comorbidities and serious adverse events (defined as any event leading to hospitalisation, whether or not it is associated with therapy). -All of the patients are flagged with the Italian Office for National Statistics, which notifies the registry of: any death (with a copy of the medical information on the death certificate) and any cancer.
Statistical analysis
The data used for this report were statistically analysed using SPSS 15 for Windows software (SPSS Inc., ILL, USA).
Results
The registry only records the data collected at baseline, after six and 12 months, and then once a year; so far, only the data relating to the first 36 months have been validated. For the purposes of this study, we considered the 1010 patients who had been followed up for at least six months plus a further 54 who, although they had been followed up for a shorter time, had already discontinued anti-TNF therapy (intention-totreat approach) (Fig. 1) . The registry includes a total of 1114 patients: 533 (47.8%) treated with infliximab, 332 (29.8%) with adalimumab, and 249 (22.4%) with etanercept. Table I shows their main demographic and clinical characteristics at the start of anti-TNF treatment. In brief, their mean age was 55.87 years and the mean duration of RA was 7.78 years; 78.6% were positive for rheumatoid factor (RF). More than 38% had comorbidities. The median number of previous DMARDs was three per patient, the vast majority of whom had previously received MTX. In combination with the biological drug, 83.9% of the patients received steroids (mean dose 4.92 mg/day), and 88.0% at least one DMARD (83.8% methotrexate at a median dose of 12.35 mg/week).
OTHER REGISTRIES OF BIOLOGICAL AGENTS
The introduction of new biological drugs for the treatment of RA and other rheumatic diseases has led to the implementation of specific registries in various countries, all of which are designed to track safety and efficacy. However, there are some differences between them. The German Registry Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) is an ongoing, intensively monitored, observational cohort study: the RA patients who start treatment with any of the licensed biological agents are enrolled in the case group, and the control subjects are those monitored from the time they start a traditional DMARD after the failure of at least one other DMARD (12) . The British Society for Rheumatology (BSR) registry is a nationwide registry of patients with any rheumatological disorder treated with biological agents that is intended to assess the long-term toxicity and benefits of their use (13) . However, one specific characteristic of the BSR register is that it also includes data from RA patients treated with conventional DMARDs in order to be able to compare the results (14) . The BIOBADASER registry, which was established in February 2000 with the aim of actively monitoring the long-term efficacy and safety of biological response modifiers in Spanish rheumatic patients, includes about 60% of the total population treated in Spain, and first defined the guidelines for TB screening and treatment (15, 16) . The Swedish rheumatology register was the first to organise registries for RA patients: ARTIS (Antirheumatic Therapies in Sweden), SSATG (Southern Sweden Anti-rheumatic Therapy Group), and STURE (Stockholm Tumor Necrosis Factor Follow-up Registry). These have demonstrated that registries are not only extremely useful in evaluating the efficacy and safety of all of the drugs used to treat RA, but also in conducting scientific research studies of everyday practice (17) . The Consortium of Rheumatology Researchers of North America (CORRONA) Registry collects clinical practice data relating to patients with RA 
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and psoriatic arthritis in order to evaluate their responses to biological agents (18) . Finally, the Czech National Registry has focused on radiographic progression in patients treated with anti-TNF agents, and reported that the improvement in everyday practice is similar to that shown by clinical trials (19) .
CONCLUSIONS
The LORHEN registry data describe the efficacy and safety of the three currently available TNF inhibitors during the first three years of treatment in a large cohort of RA patients from Lombardy, Italy.
